YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $28 | $246 | $370 | $1 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $502 | $447 | $468 | $309 |
| Inventory | $228 | $203 | $185 | $167 |
| Other Curr. Assets | $85 | $6 | $12 | $19 |
| Total Curr. Assets | $842 | $903 | $1,036 | $1 |
| Property Plant & Equip (Net) | $414 | $481 | $583 | $565 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $73 | $71 | $78 | $81 |
| Long-Term Investments | $0 | $0 | $0 | $200 |
| Tax Assets | $28 | $24 | $2 | $3 |
| Other NC Assets | $10 | $34 | $21 | -$649 |
| Total NC Assets | $525 | $610 | $684 | $200 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,368 | $1,513 | $1,720 | $201 |
| Liabilities | – | – | – | – |
| Payables | $50 | $68 | $80 | $31 |
| Short-Term Debt | $391 | $324 | $198 | $116 |
| Tax Payable | $3 | $3 | $0 | $1 |
| Deferred Revenue | $1 | $2 | $2 | $2 |
| Other Curr. Liab. | $380 | $406 | $377 | -$150 |
| Total Curr. Liab. | $825 | $802 | $659 | $0 |
| LT Debt | $24 | $101 | $300 | $265 |
| Deferred Rev, NC | $16 | $20 | $24 | $7 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | -$265 |
| Other NC Liab. | $3 | $5 | $9 | -$274 |
| Total NC Liab. | $43 | $126 | $333 | $20 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $7 | $11 | $15 |
| Total Liabilities | $868 | $928 | $991 | $20 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $1,370 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$2,407 | -$2,308 | -$1,874 | -$19 |
| AOCI | -$57 | -$58 | -$54 | $83 |
| Other Equity | $2,964 | $2,951 | $2,657 | $1,198 |
| Total Equity | $500 | $585 | $728 | $181 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,368 | $1,513 | $1,720 | $201 |
| Net Debt | $386 | $178 | $129 | $380 |